Lidia Aguilera posted this:
Technology Transfer Officer at University of Luxembourg
Universitat Politècnica de Catalunya - UPC posted this:New inorganic cement for biomedical applicationsA novel magnesium phosphate cement with good properties for clinical applications has been patented and developed. It is envisaged as an excellent root canal filler for endodontic treatments, improving the commercial materials currently used for this application. Partners to establish commercial agreements along with technical cooperation are sought.
UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera
Laijo Jose posted this:
Manager-Tech Transfer at Centre For Future (CFF)
Universitat de Lleida posted this:LapC-FORCE: Surgical device to improve laparotomy closure for incisional hernia preventionA multidisciplinary team involving doctors and engineers developed a medical device to cover the surgeons’ need at the moment of closing a laparotomy. With real-time information on force and distance, surgeons may decide the most appropriate closure technique and materials to be used for each single patient for reducing the laparotomy’s closing force and therefore, to prevent incisional hernias. We currently have a prototype medical device that measures the closing force between edges in a laparotomy. It was designed and tested in non-regulatory preclinical trials using pigs. We are looking for an industrial partner with expertise in the sector of medical devices willing to add in its product pipeline a new surgery device to assist surgeons during a laparotomy. The type of partner sought is mainly for regulatory development and commercialization under a technology license agreement.
Cracow University of Technology posted this:Synthetic bone substitute with antimicrobial properties (antibacterial and antifungal).The offered product is a material used for reconstruction of skeletal system bone with long-term antimicrobial operation, in contrast to the pure hydroxyapatite most widely used in regenerative medicine. The resulting materials can be designed in many industries, but the emphasis is mainly focused on medical, dental and pharmaceutical applications.
Cracow University of Technology posted this:Hydrocolloid nanocomposite and production method thereof. Product is dedicated for superficial wounds in a shape of platesNanostructured silver is suspended in the gelling environment, which is a precursor of a colloidal system. A gelatin which is a natural protein polymer is a gelling environment. Nanosilver, due to its characteristics is widely used. The best-known advantage of silver nanoparticle is its antibacterial activity.
Universidad de Alcalá-OTRI posted this:Double port injector to corneal transplant DMEKThe Reseacrh group in Cell biology of solid tumors and tisular regeneration from Alcala University and the Research group in Cellular Engineering from University from Hospital La Paz, have developed a new injector designed to reduce endotellial damage during the corneal endothelial graft implantation in eye´s anterior chamber. The group is looking for cooperation or commercial agreement with companies manufacturers of sanitary products and medical devices, ophthalmological clinics and hospitals.
IMIM Institut Recerca Hospital del Mar posted this:New method for the determination of the risk of atypical fractures in patients treated with bone remodelling inhibitors.Up to date there is not any technology for detecting the risk to suffer atypical fractures related to long-term treatment with bone remodelling inhibitors. The invention will be of usefulness for individualize treatments in patients treated with bone remodelling inhibitors by detecting the individual risk of suffering atypical fractures. The invention is planned to be included into an in-vitro diagnostic tool for the atypical fracture, which will be included into standard disease management protocols and therefore used routinely by physicians prior to and after the prescription of bone remodelling drugs and further osteoporosis drugs. Osteoporosis is a progressive bone disease with a characteristic decrease in bone mass and density which can lead to an increased risk of fracture. There are two types of osteoporosis: •Type 1: most common in women after menopause, named postmenopausal osteoporosis •Type 2: Senile osteoporosis, occurs mostly after age of 75 years and has equally effect in women and in men Based on the WHO diagnostic criteria, approximately 22 million women and 5.5 million men aged between 50 and 84 years had osteoporosis in the European Union (EU) in 2010, whilst osteoporosis can be found in the list of 10 most important diseases named by the WHO. Due to changes in population demography, the number of men and women with osteoporosis might rise from 27.5 million in 2010 to 33.9 million in 2025, corresponding to an increase of 23%. The number of new fractures in the EU in 2010 was estimated at 3,5 million cases, in between these approximately 620.000 hip fractures, 520.000 vertebral fractures, 560.000 forearm fractures and 1.800.000 fractures of i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures. Two thirds of all fractures occurred in women. In 2010, the number of deaths causally related to fractures was estimated at 43.000. The corresponding cost of osteoporosis in the EU, also in 2010 figures, including pharmacological intervention, was estimated at €37 billion out of which costs of treating fractures represented 66%, pharmacological prevention 5% and long term fracture care 29%. The total health burden was estimated at 1 180 000 lost Quality Adjusted Life Years (QALY) for the EU. The total cost in the EU might rise from €98 billion in 2010 to €120 billion Euro in 2025. The use of osteoporosis drugs has increased considerably. Approved pharmacological interventions (bisphosphonates, strontium ranelate, raloxifene, denosumab and parathyroid hormone peptides) are widely available but their use is restricted by reimbursement policies. Alendronate (a bisphosphonate) is the most commonly prescribed agent, accounting for approximately a quarter of the total value of sales. The potential users/partners are pharmaceutical companies, excluding pure generic companies (lacking development resources, relevant lobbying and sales channel to the policy makers and practitioner) selling drugs in the indication osteoporosis
DIT Hothouse posted this:Optimisation of Posterior Spinal Dynamic (PSD) Stabilisation SurgeryOptimising spinal surgery techniques through the use of a hip and spine simulator and a tension and torsion test machine to treat spinal patient such as those with crushed vertebra and spinal deformities, like scoliosis.
Universidad de Alcalá-OTRI posted this:Double mesh prosthesis that corrects defects in the abdominal wall and prevents adhesion formation at the peritoneal interfaceA research group from the Surgery Department of Alcala University has designed an implantable prosthesis made of two meshes joined together, for abdominal surgery uses. This prosthesis prevents the erosion of the viscera by promoting mesothelial deposition. Both meshes induce fibroblast proliferation and collagen deposition achieving the definitive repair of the defect at the expense of connective tissue. This research group is looking for manufacturing and license agreements.
Technology Transfer Office
Ventura Medical Technologies posted this:A new surgery kit for Pectus ExcavatumFrom the cooperation between Ventura Medical Technologies and Hospital Parc TaulÃ, a new method, Taulinoplastia, and a new surgery kit, Pectus Up, are born to correct the Pectus Excavatum. This new technique presents suitable advantages over current used methods. Pectus Up is a set of tools and implants manufactured with the aim of treating Pectus Excavatum with the Taulinoplastia, being less painful and with a reduced post-operative time than other methods.
Unitat de Valorització de la URV posted this:
Licensing Manager at Fundació URV
Technology Transfer OfficeView Profile
Biomedicine and Biotechnology Center - Leipzig University posted this:Peptide for Titanium and Biomaterial Surface Coating for Enhanced OsseointegrationOur research involves the modification of a recently patented molecule that contains L-3,4-dihydroxyphenylalanine (DOPA) and other bonding peptides to increase osseointegration on metal surfaces, particularly titanium. Lab results show that when coated with this molecule, titanium surfaces showed increased signs of bio-compatibility, which is backed up by published scientific research. The technology has the potential of improving osteosynthesis and orthopedic implants, as well as many other types of surgical implants. The BBZ is looking for licensing, joint R&D, or ownership opportunities regarding this technology.